Drug Trial Radar · NCT05877430
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 11, 2023
Primary completion
Jul 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- CJ Bioscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.
Conditions
- NSCLC
- HNSCC
- Melanoma
- Metastatic Cancer
- Advanced Solid Tumor
- Advanced Cancer
Interventions
CJRB-101Drug
In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
Pembrolizumab injectionDrug
200 mg given by intravenous (IV) infusion once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Phase 1&2] Tolerability and Safety: Incidence of Adverse EventsTime frame: Maximum 2 years
- [Phase 2] EfficacyTime frame: Maximum 2 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.